Compounds > 2-(quinolin-2-ylmethylene)hydrazinecarbothioamide
Page last updated: 2024-12-11

2-(quinolin-2-ylmethylene)hydrazinecarbothioamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(quinolin-2-ylmethylene)hydrazinecarbothioamide: a topoisomerase II alpha inhibitor; has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6871286
CHEMBL ID215065
MeSH IDM0546471

Synonyms (13)

Synonym
[(e)-2-quinolylmethyleneamino]thiourea
2-formylquinoline thiosemicarbazone
nsc79295
nsc-79295
1-(quinolin-2-ylmethylene)thiosemicarbazide
2-(quinolin-2-ylmethylene)hydrazinecarbothioamide
bdbm50199450
CHEMBL215065 ,
(2e)-2-(quinolin-2-ylmethylidene)hydrazinecarbothioamide
STK841136
AKOS005625219
AB01320283-02
NCGC00324159-01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)70.00000.03403.987110.0000AID613824
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)10.00000.00050.939410.0000AID272786; AID272787
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID477998Antiproliferative activity against human HeLa cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID477997Inhibition of human topoisomerase 2 alpha-mediated decatenation of kDNA at 100 uM after 15 mins2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID477995Antiproliferative activity against human HL60 cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID272787Inhibition of chymotrypsin-like activity of proteasome in intact LnCaP cells2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
AID272782Induction of apoptosis in LnCaP cells assessed as PARP cleavage by Western blot analysis2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
AID272781Cytotoxicity against human PC3 cell line by MTT assay after 72 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
AID272783Inhibition of proteasome in intact LnCaP cells measured as accumulation of ubiquitinated protein at 10 uM by Western blot analysis2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
AID613824Inhibition of diphenolase activity of mushroom tyrosinase using L-DOPA as substrate preincubated for 5 mins by spectroscopic method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Refinement of arylthiosemicarbazone pharmacophore in inhibition of mushroom tyrosinase.
AID272780Cytotoxicity against human LnCaP cell line by MTT assay after 72 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
AID478000Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
AID272785Inhibition in LnCaP cell line growth by ELISA apoptosis assay upto 20 uM2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
AID272784Induction of apoptosis in LnCaP cells measured by hydrogen peroxide assay2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
AID272786Inhibition of chymotrypsin-like activity in rabbit 20S proteasome2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells.
AID477994Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		2.0510acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0510nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
kojic acid
[no description available]		2.06104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
vincristine
[no description available]		2.0510acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
doxorubicin hydrochloride
[no description available]		2.0510anthracycline
2-formylpyridine thiosemicarbazone
2-formylpyridine thiosemicarbazone: structure; RN given refers to parent cpd without isomeric designation		2.0610
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
3-aminopyridine-2-carboxaldehyde thiosemicarbazone: a neuroprotective agent; structure given in first source		2.1110
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		02.0310
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0310
Hepatocellular Carcinoma
[description not available]		02.0610
Cancer of Liver
[description not available]		02.0610
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0610
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0610